A network-based approach for predicting key enzymes explaining metabolite abundance alterations in a disease phenotype by Peyton, J. et al.
  
 
 
 
 
Peyton, J., Tobalina, L., Prada Jimenez de Cisneros, J., and Planes, F.J. (2013) A 
network-based approach for predicting key enzymes explaining metabolite 
abundance alterations in a disease phenotype. BMC Systems Biology, 7 (62). 
ISSN 1752-0509 
 
 
Copyright © 2013 The Authors 
 
 
 
http://eprints.gla.ac.uk/84721 
 
 
 
Deposited on: 23 August 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Pey et al. BMC Systems Biology 2013, 7:62
http://www.biomedcentral.com/1752-0509/7/62METHODOLOGY ARTICLE Open AccessA network-based approach for predicting key
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alterations in a disease phenotype
Jon Pey1†, Luis Tobalina1†, Joaquín Prada J de Cisneros1,2 and Francisco J Planes1*Abstract
Background: The study of metabolism has attracted much attention during the last years due to its relevance in
various diseases. The advance in metabolomics platforms allows us to detect an increasing number of metabolites
in abnormal high/low concentration in a disease phenotype. Finding a mechanistic interpretation for these
alterations is important to understand pathophysiological processes, however it is not an easy task. The availability
of genome scale metabolic networks and Systems Biology techniques open new avenues to address this question.
Results: In this article we present a novel mathematical framework to find enzymes whose malfunction explains
the accumulation/depletion of a given metabolite in a disease phenotype. Our approach is based on a recently
introduced pathway concept termed Carbon Flux Paths (CFPs), which extends classical topological definition by
including network stoichiometry. Using CFPs, we determine the Connectivity Curve of an altered metabolite, which
allows us to quantify changes in its pathway structure when a certain enzyme is removed. The influence of enzyme
removal is then ranked and used to explain the accumulation/depletion of such metabolite. For illustration, we
center our study in the accumulation of two metabolites (L-Cystine and Homocysteine) found in high concentration
in the brain of patients with mental disorders. Our results were discussed based on literature and found a good
agreement with previously reported mechanisms. In addition, we hypothesize a novel role of several enzymes for
the accumulation of these metabolites, which opens new strategies to understand the metabolic processes
underlying these diseases.
Conclusions: With personalized medicine on the horizon, metabolomic platforms are providing us with a vast
amount of experimental data for a number of complex diseases. Our approach provides a novel apparatus to
rationally investigate and understand metabolite alterations under disease phenotypes. This work contributes to the
development of Systems Medicine, whose objective is to answer clinical questions based on theoretical methods
and high-throughput “omics” data.Background
Metabolism comprises the inter-conversion of small
molecules (metabolites) through enzymatically catalyzed
biochemical reactions. These metabolites play a key role
in different cellular functions, ranging from energy pro-
duction to biosynthesis of complex macro-molecules.
Metabolic alterations have been reported in a number of
multifactorial diseases [1]. In particular, their abnormal* Correspondence: fplanes@ceit.es
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reproduction in any medium, provided the orrole in cancer cells currently constitutes a hot topic in
the field of molecular systems biology [2]. Several import-
ant works have recently emphasized this feature of cancer
cells and have thrown light on their underlying complex
regulatory processes [3], indicating novel ways to target
malignant tumors. Extending the study of metabolic pro-
cesses to other diseases is essential to complete our under-
standing of their key pathophysiological processes.
For this purpose, it is of utmost importance to exploit
the information given by the spearhead experimental
technologies that directly or indirectly provide a meta-
bolic picture of different human samples. Gene expres-
sion analysis [4], quantitative protein measurement [5],. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are the most widespread techniques when analyzing
metabolic processes. Their integration into different
mathematical models, mainly based on linear and non-
linear optimization, has already provided relevant in-
sights into different disease phenotypes [8,9]. Continuing
this integration task is currently a relevant area in sys-
tems biology and medicine [10].
The field of metabolomics has experienced a remarkable
advance in mass spectrometry techniques and currently
can measure hundreds of metabolites simultaneously [11].
In contrast with gene and protein expression, which are
subject to stringent regulatory processes, metabolite abun-
dance is closer to biochemical activity and therefore easier
to correlate with cellular phenotype [12], as summarized in
Figure 1A. For this reason, metabolomics has become a
powerful approach for clinical diagnostics and personalized
medicine [13]. In addition, metabolomics data potentially
involves rich and valuable information to understand meta-
bolic alterations underlying a disease phenotype. However,
the detailed mechanistic interpretation of changes in me-
tabolite abundance is not straightforward, as they may arise
from different sources, some of them unlikely to be related
with the phenotype of interest. Therefore, establishingFigure 1 Schematic representation of A) different levels of complexiteffective methods to provide a functional interpretation to
metabolomics data is required.
Assorted methods can be found in the literature to in-
terpret metabolomics data based on curated metabolic
pathways and networks [14]. On the one hand, kinetic
[15] and thermodynamic [16] approaches directly relate
metabolite concentrations with the activity of enzymes
in a particular metabolic pathway. However, due to the
high computational cost and intensive prior knowledge
(kinetic constants/proteomics data) required by these
methods, they have been directly applied to a limited num-
ber of metabolic pathways [17]. On the other hand, several
tools mapping identified metabolites onto pre-defined
metabolic pathways have been developed [18]. However, as
pre-defined pathways do not fully capture complex meta-
bolic states, it is difficult to extract the mechanism(s) re-
sponsible for changes in metabolite levels. To overcome
this issue, different tools using network-based pathway
(mathematical) definitions were introduced [19,20]. These
methods take advantage of the plasticity and connectivity
of genome-scale metabolic networks to provide a more
compact functional view of metabolomics data [21].
In this article, we address the question as to find the
key enzymes regarding the accumulation/depletion ofy at molecular level; B) the purpose of our methodology.
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olite abundance is recognized as the most accurate indi-
cator of phenotype, deciphering enzymes that regulate
such phenotype certainly constitutes a relevant question
and links metabolite data with upstream molecular mech-
anisms. A similar investigation was conducted by Cakir
et al. [22], where enzymes with statistically significant co-
ordinated changes in the abundance of surrounding me-
tabolites were identified. Given the high inter-connectivity
of metabolic networks, key enzymes are not necessarily
topological neighbors of identified metabolites, as as-
sumed in that work. Instead, enzymes at considerable dis-
tances from identified metabolites may exert control on
the flux of their underlying biosynthesis and degradation
pathways and therefore alter their concentration.
In this light, we introduce a novel theoretical concept
termed “connectivity curve (CC)”, which summarizes the
structure of pathways consuming (producing) an identi-
fied metabolite and their underlying distances in a
genome-scale metabolic network. Pathway distances are
used as a clue for their fluxes in line with several theor-
etical works that show that shorter pathways support a
higher flux than longer pathways [23-25]. Using CCs we
examine whether the removal of a certain enzyme in-
creases degradation (biosynthesis) pathway distances of
an identified metabolite, which therefore would decrease
its degradation (biosynthesis) fluxes and thus may lead
to its accumulation (depletion).
In order to determine metabolic pathways and distances
in CCs, we used Carbon Flux Paths (CFPs), a network-
based pathway concept recently introduced by Pey et al.
[26]. The CFP approach searches for simple paths (in the
graph theoretical sense) between a given pair of source/
target metabolites. In addition, the CFP approach ensures
that the obtained path satisfies a relevant set of biophys-
ical constraints, such as mass balance (usually referred to
as steady-state condition), going beyond classical path
finding approaches.
Based on CCs, we rank enzymes in the network as re-
sponsible for the accumulation (depletion) of an identified
metabolite. To assess the performance of our approach,
we investigated key enzymes corresponding to the accu-
mulation of two metabolites (L-Cysteine and Homocyst-
eine) closely related with mental disorders.
Results and discussion
This section is organized as follows. We first illustrate
the concept of CCs and several parameters arising from
them by means of a classical metabolic network re-
presenting glucose metabolism [27]. This example is also
used to describe the statistical validation conducted. We
then discuss the resulting key enzymes obtained when ap-
plied our approach to explain the accumulation of L-Cyst-
eine and Homocysteine in mental disorders.Connectivity Curve (CC) approach
Assume a metabolite is identified in significantly high
concentration and we are concerned with finding en-
zymes whose malfunction explains its accumulation.
For this purpose, we introduce the connectivity curve
(CC), which plots the number of metabolites connected
after moving away n steps (reactions) from such identi-
fied metabolite. In order to determine whether this
identified metabolite is connected to other metabolites
and their distances, we used the Carbon Flux Paths
(CFPs) approach. The CFP algorithm searches for the
shortest path between a pair of source and target metab-
olites in the context of the metabolic network, which is
here represented as a metabolite-metabolite directed
graph. To avoid not biologically meaningful shortcuts,
we removed arcs not involving an effective carbon ex-
change. The use of integer linear programming allows
us to impose further constraints. In particular, we in-
corporate reaction stoichiometry and force paths to
satisfy the mass balance equation and perform in
sustained steady-state. Further details can be found in
Methods section.
To illustrate the concept of CCs, consider the example
metabolic network in Figure 2 based on Schuster et al.
[27]. This network comprises the major part of the mono-
saccharide metabolism, involving glycolysis, pentose phos-
phate pathway (PPP) and part of gluconeogenesis, as well
as an input flux of Glucose (D-Glc) and three output
fluxes of CO2, ribose-5-phosphate (R5P) and Pyruvate
(Pyr). We assumed that Glucose-6-Phosphate (G6P) is
identified in high concentration and therefore enzymes re-
sponsible for its accumulation are evaluated. Based on
CFPs, we calculated the minimum number of steps (reac-
tions) necessary to reach any metabolite from G6P, e.g. 7
steps are required to reach Pyr. Note that the CFP ap-
proach is applied once for each metabolite different to
G6P. Red solid line in Figure 3A shows the CC for G6P.
We can observe that from G6P 2 metabolites can be
reached in 1 step; 8 metabolites in 2 steps, etc.; finally
reaching 17 metabolites in 7 steps. Full details can be
found in the Additional file 1.
We assume that distances (number of steps) provide a
clue of the degradation fluxes (velocity) of the metabol-
ite under study, namely shorter distances imply higher
fluxes. A more efficient use of resources via shorter
pathways overall allows reactions to carry higher fluxes,
which indirectly increases the capacity to produce bio-
mass and energy. In particular, shorter pathways reduce
mass leaks, wasted energy and the amount of protein re-
quired to catalyze a process, as discussed in a number of
theoretical works [23-25]. There is also experimental
evidence in E. coli evolution studies that the decrease in
the number of active reaction steps and increase in
growth rate occur simultaneously [28].
Figure 2 Example metabolic network involving glycolysis and pentose phosphate pathway [27]. Reaction arcs with a white circle indicate
the reaction is reversible. Abbreviations of enzymes: Eno, enolase; Fba, fructose 1,6-bisphosphate aldolase; Fbp, fructose 1,6-bisphosphatase; Gap,
glyceraldehydes 3-phosphate dehydrogenase; Gnd, phosphogluconate dehydrogenase (decarboxylating); Gpm, phosphoglycerate mutase; Hex1,
hexokinase; Pfk, 6-phosphofructokinase; Pgi, phosphoglucoisomerase; Pgk, phosphoglycerate kinase; Pgl, phosphogluconolactonase; Pyk, pyruvate
kinase; Rpe, ribulose-phosphate 3-epimerase; Rpi, ribose 5-phosphate isomerase; Tal, transaldolase; TktI, transketolase; TktII, transketolase; TpiA,
triosephosphate isomerase; Zwf, glucose 6-phosphate dehydrogenase. Abbreviation of metabolites: 1,3BPG, 3-Phospho-D-glyceroyl phosphate;
2PG, D-Glycerate 2-phosphate; 3PG, 3-Phospho-D-glycerate; 6PG, 6-Phospho-D-gluconate; D-Glc, D-Glucose; DHAP, Dihydroxyacetone phosphate;
Ery4P, D-Erythrose 4-phosphate; F6P, D-Fructose 6-phosphate; FP2, D-Fructose 1,6-bisphosphate; G6P, D-Glucose 6-phosphate; GAP,
Glyceraldehyde 3-phosphate; GO6P, 6-phospho-D-glucono-1,5-lactone; PEP, phosphoenolpyruvate; Pyr, pyruvate; R5P, alpha-D-Ribose
5-phosphate; Ru5P, D-Ribulose 5-phosphate; Sed7P, sedoheptulose 7-phosphate; Xyl5P, D-Xylulose 5-phosphate.
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changes in CFP distances in different scenarios. We par-
ticularly focus here on single reaction knockouts, i.e. we
remove one-by-one each reaction from the metabolic net-
work and re-calculate the CC for the identified metabolite.A
Figure 3 Results arising from the example network in Figure 2. A) Co
parameter (ΔLj), disconnected metabolites and p-value for each enzyme knTo illustrate this, green dashed line in Figure 3A shows
the CC for G6P when phosphoglucoisomerase (Pgi) was
knocked out. We can observe now that from G6P 1 me-
tabolite can be reached in 1 step; 2 metabolites in 2
steps; 3 metabolites in 3 steps, etc.; finally reaching 17B
nnectivity curve for G6P in different scenarios; B) Length increasing
ockout. Shaded reactions do not satisfy filtering criterion.
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Pgi causes an increase in the distances from G6P to the
rest of the metabolic network. The effect of this knock-
out in the set of CFPs from G6P to the rest of metabo-
lites can be found in the Additional file 1. We repeat the
procedure for each enzyme in the example network.
We hypothesize that the distance increase observed in
our CCs approach after knocking-out a particular en-
zyme represents a decrease in the degradation flux of
our identified metabolite, which may lead to its accumu-
lation. As noted above, the basis is that shorter paths
carry higher flux [23-25] and thus their blockage would
lead to the usage of less efficient alternative pathways
with the corresponding concentration alterations. There-
fore, the malfunction of such enzymes may explain a sig-
nificant increase in the concentration of the metabolite
under study. Since we assume that the identified metab-
olite is closely related with a certain disease phenotype,
these enzymes may constitute regulatory key points for
such phenotype.
In order to quantitatively measure the increase in dis-
tances from the metabolite under study to the rest of the
metabolic network when enzyme j is knocked out, we
introduce the length increasing parameter (ΔLj), which
essentially averages distance differences between the
knockout and wild-type scenarios (see Methods section).
Note that we may have the case that, when an enzyme is
knocked out, a number of metabolites become discon-
nected from the metabolite under study. In order to
determine ΔLj, we only consider changes in the distance
to metabolites that remain connected after the knock-
out. To illustrate this consider the blue dotted line in
Figure 3A, which represents the CC for G6P when
triosephosphate isomerase (TpiA) was knocked out. We
can observe that 16 metabolites are now reached from
G6P, namely one less than in the wild-type scenario. In
particular, dihydroxyacetone phosphate (DHAP) cannot
be reached from G6P since TpiA is essential for its mass
balance. Although we can still find routes linking G6P
and DHAP, none of them can be mass balanced (see
Additional file 1).
This parameter (ΔLj) allows us to rank enzymes as re-
sponsible for the accumulation of the metabolite under
consideration. Clearly, we are interested in enzymes that
when knocked out present a high ΔLj, which can poten-
tially explain the accumulation of the metabolite of
interest. Figure 3B details ΔLj in our example metabolic
network. Pgi constitutes the most relevant enzyme for the
accumulation of G6P. Indeed, blocking Pgi eliminates the
classical pathways for glucose consumption, but others
are still available. This can be easily observed in the ana-
lysis of Elementary Flux Modes (EFMs) conducted in the
seminal work of Schuster et al. [27], namely few EFMs
consuming G6P are left active after the knockout of Pgiand they involve more steps, for example, to reach Pyr.
Note that we extract similar conclusions as when using
the EFMs analysis because our CFP approach forces the
mass balance constraint in the resulting paths. However,
the use of EFMs approach for large metabolic networks is
difficult due to combinatorial explosion [29]. We show
below that our approach scales well even in such large
metabolic networks.
We are aware of the fact that other mechanisms may
lead to an accumulation or depletion of metabolites. For
example, up-regulation of biosynthetic pathways of the
metabolite under study may explain its accumulation.
Note however that this is more difficult, since an in-
crease in pathway flux is typically achieved if all enzymes
[30] or (at least) a considerable number of enzymes in a
pathway [31,32] are over-expressed. For simplicity, this
strategy has been not considered in this work.
We would like to clarify that we have focused on the
accumulation of identified metabolites, but the analysis
of depleted metabolites can be easily accomplished.
Indeed, the definition of CCs would slightly change, in-
volving the number of metabolites reaching the metab-
olite under consideration after moving back n steps.
Similarly, distances in CC provide a clue as to the bio-
synthesis fluxes of the identified metabolite. Therefore,
when studying a depletion instead of an accumulation,
we would search for enzymes that, when knocked-out,
significantly increase such distances. This would de-
crease the biosynthesis flux of the metabolite under
study and therefore lead to its depletion.
Other issues: filtering criterion and specificity
As noted above, the knockout of certain enzymes may
bring about the disconnection of pairs of metabolites.
Clearly, if key metabolites are disconnected, important
damage in cellular functions may be caused, even lead-
ing to cellular death. As we assume that phenotypic
changes in metabolite abundance are more subtle, we
are not aiming here at enzyme knockouts producing
radical disconnections. Instead, we search for knockouts
impairing but not disrupting the normal functioning of
metabolic processes. For this purpose, we only consider
enzymes that when knocked out do not alter the con-
nectivity between the inputs (medium metabolites) and
outputs (excreted metabolites) of the metabolic network.
Note that we could impose other criteria, e.g. guarantee-
ing a particular biological function such as biomass pro-
duction. To illustrate this, in the example in Figure 2 we
have as inputs D-Glc and as outputs Pyr, CO2 and R5P.
It can be easily observed that the knockout of pyruvate
kinase (Pyk) disconnects the biosynthesis of Pyr from D-
Glc, which violates our rule above and therefore it is not
considered further. Instead, when TpiA is knocked out, al-
though DHAP is disconnected from G6P, the connectivity
Table 1 Details of 4 top-ranked reactions responsible for
the accumulation of LCystin
Reaction names ΔLj p-value
Cysteine oxidase 0.700348 0.0060
Formaldehyde dehydrogenase 0.637731 0.0190
S-formylglutathione hydralase 0.637731 0.0190
Sulfite oxidase 0.636891 0.0060
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therefore it is a viable knockout. Rows in the table in
Figure 3B corresponding to enzymes violating this rule are
shaded in grey. To conduct this task, we again used the
CFPs approach.
For the sake of simplicity, it would be preferable to
relate each enzyme with a unique metabolite accumula-
tion, i.e. knocking out a certain enzyme would only lead
to significant changes in distances from a unique metab-
olite. To evaluate this, we introduce a parameter re-
presenting the specificity of the actual enzyme knockout
for the accumulation of the metabolite under study. In
particular, we assigned a p-value for each enzyme, which
defines the probability of finding such enzyme in an
equal/better position in the ranking of a different
metabolite. Details can be found in Methods section.
Figure 3B includes the p-values for each enzyme in our
example metabolic network. Note here that the best p-
value that can be attained in our approach is one over
the number of metabolites in the network under study.
Given the reduced number of metabolites involved in
this example network, this explains why p-values are
not particularly low. As can be seen in the next section,
this lack of statistical power is overcome as the network
size increases. The lowest p-value is found for Pgi,
which indicates that its knockout leads to the accumula-
tion of a reduced set of metabolites, clearly including
G6P. As noted above, we selected the most parsimoni-
ous solution and focused on specific knockouts, i.e.
those having a small p-value. But a high p-value might
not be undesired for other questions, since complex dis-
eases may potentially present alterations in the concen-
tration of more than one metabolite.
Case studies: metabolite accumulation in mental
disorders
In this sub-section we apply the approach presented
above to rank enzymes responsible for the accumulation
of L-Cysteine (LCystin) and Homocysteine (HCys), me-
tabolites found in high concentration in some mental
disorders. For this purpose, we used the human metabolic
network Recon1 [33]. As others methods from constraint-
based modeling, the application of our approach is
dependent on the definition of the growth medium, i.e.
available substrates. In this work a minimal medium based
on glucose and amino acids was used [34]. We allow a
way out of the network for exchange (external) metabo-
lites found in Recon1 not included in the growth medium.
As noted above, to avoid not meaningful shortcuts
when applying the CFP method, we removed arcs not
involving an effective carbon exchange in each reaction.
Based on Recon1, a list of pairs of metabolites exchan-
ging carbon atoms for each reaction was built (see
Additional file 2). We also neglected carbon arcscorresponding to hub metabolites, namely CoA, CO2,
AMP, ATP and ADP, as typically done in others works
[35]. In addition, given their participation in a high
number of reactions, they can cause not meaningful
shortcuts and disrupt carbon flux along the path. Note
however that those metabolites were not removed from
the stoichiometric matrix and therefore they must be
mass balanced (see Methods section).
L-Cystine accumulation
The accumulation of LCystin is a relevant phenotype in
Cystinosis, which may cause different tissue failure. In
particular, brain atrophy was observed in this condition
[36,37]. The principal cause of this accumulation is asso-
ciated with the malfunction of the LCystin transport
across lysosomal membrane [38].
Using the approach presented above, we explore alter-
native scenarios leading to LCystin accumulation in the
context of brain damage. Table 1 summarizes results
arising from our approach (full results can be found in
Additional file 3). In particular, we present details as to
the four top-ranked enzymes responsible for the accu-
mulation of LCystin. In order to evaluate the perform-
ance of our method, we discuss below the role of these
enzymes in several mental disorders.
The first enzyme in the ranking is cysteine oxidase
(CYSO), also referred to as cysteine dioxigenase, which
presents ΔLj≈0.7. Perry et al. [39] reported a decreased
activity of this enzyme in the brain of a Pantothenate
kinase-associated neurodegeneration (PKAN) patient (dis-
ease formerly known as Hallervorden-Spatz syndrome).
This syndrome is characterized by rigidity, spasticity, dys-
tonia and dementia among others. In that work they also
found an accumulation of LCystin in the globus pallidus
of the brain, precisely the same region where they mea-
sured the decreased activity of CYSO, clearly in line with
our hypothesis. It is relevant to note that we are aiming at
enzyme malfunctions that could lead to LCystin accumu-
lation and our first predicted enzyme turned out to have
been previously related with this phenotype in the litera-
ture. It is worth to mention that the length of CFPs be-
tween LCystin and more than three hundred metabolites
were affected by the removal of this enzyme. This fact
makes infeasible to systematically arrive at a clear network
that summarizes pathway changes for visual inspection,
Table 2 Details of 4 top-ranked reactions responsible for
the accumulation of HCys
Reaction names ΔLj p-values
Phosphatidylethanolamine N-methyltransferase 0.768421 0.0010
S-Adenosyl-L-methionine reversible transport,
mitochondrial
0.768421 0.0010
Phosphatidylserine decarboxylase 0.767333 0.0130
Phosphatidylserine flippase 0.767333 0.0130
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parametric methods as the one introduced here.
In the second and third position appear formaldehyde de-
hydrogenase (FALDH) and S-Formylglutathione hydralase
(SFGTH) both with ΔLj=0.638. FALDH is currently split
into two independent reactions: EC 4.4.1.22 Glutathione-
dependent formaldehyde-activating enzyme, GFAE, and
EC 1.1.1.284 S-(hydroxymethyl) glutathione dehydrogen-
ase, ADH3 [40].
GFAE consumes Formaldehyde, a highly toxic metab-
olite previously reported in several mental disorders
[41,42]. A known mechanism reducing this toxic metab-
olite is the formaldehyde oxidation pathway [43]. In es-
sence, this pathway comprises the enzymes under study:
GFAE, ADH3 and SFGTH. Thus, these three enzymes
are of utmost importance to reduce Formaldehyde con-
centration. In light of this, some authors proposed to
increase the activity of these Formaldehyde-consuming
enzymes so as to decrease brain damage [42,44]. We
suggest that this pathway protects brain against damaging
processes by reducing not only Formaldehyde presence
but also LCystin concentration. Note that FALDH and
SFGTH have a greater p-value, which indicates that they
are not as specific to the LCystin accumulation as CYSO.
Hence, finding effects on other metabolites in the litera-
ture does not seem out of place.
The last enzyme included in Table 1 is sulfite oxidase
(SULFOX) with ΔLj=0.637. An insufficiency of this en-
zyme causes a disease known as sulfite oxidase defi-
ciency, characterized by neurological disorders, mental
retardation and brain degradation [45]. Dublin et al. [46],
measured an accumulation of LCystin in urine in a patient
with sulfite oxidase deficiency. However, the same study
reported a depletion (not an accumulation) of this metab-
olite in blood. In any case, this study suggests a connec-
tion between LCystin and sulfite oxidase deficiency.
Interestingly, note there is no carbon flux from LCystin to
any metabolite taking part in SULFOX, since they are
inorganic metabolites (Sulfite, Sulfate, H2O and H
+) and
cofactors (Ferricytochrome c and Ferrocytochrome c).
However, this reaction is important to mass balance the
obtained paths. When it is knocked out, original short
paths become unavailable and the average distance in-
creases. This remark highlights the importance of balan-
cing the paths as previously claimed in Pey et al. [26].
Homocysteine accumulation
A similar study was conducted for the accumulation of
HCys, which has been previously linked to Alzheimer's
disease (AD) [47,48]. Full results when our approach
was applied in this scenario can also be found in
Additional file 3. The four top-ranked enzymes are
shown in Table 2. A brief discussion as to the relevance
of these enzymes in AD is presented below.The first enzyme in the ranking is Phosphatidyletha-
nolamine N-methyltransferase (PEMT), with ΔLj=0.768.
This mitochondrial enzyme catalyzes the methylation of
Phosphatidylethanolamine (PE) producing Phosphat-
idylcholine (PC). This enzyme has been previously re-
lated with AD. In Johnson and Blusztajn [49], this
enzyme is proposed as a possible target for AD. In par-
ticular, they suggest that activating PEMT would be
beneficial for cholinergic neurons, since PC production
would be promoted. A similar conclusion was achieved
in the work of Guan et al. [50]. They localized a deficit
of this enzyme in the frontal cortex of brain affected
with AD, precisely one of its most affected regions.
From a different angle, Selley [51], aims at the accumu-
lation of S-Adenosyl-L-homocysteine (SAH) as a possible
cause for the malfunction of this enzyme in liver for AD
patients. Interestingly, in that work evidences are also
found to relate the inhibition of PEMT and the accumu-
lation of HCys, which is in line with our hypothesis.
S-Adenosyl-L-methionine reversible transport (SLC25A26)
is found in the second position in Table 2, with ΔLj=0.768.
This enzyme transports mitochondrial SAH into cytosol
and cytosolic S-Adenosyl-L-methionine (SAM) into mito-
chondria. It should be pointed out that this is the only
mechanism producing mitochondrial SAM in the network
under study [33]. As this metabolite is required for the
activity of PEMT (first enzyme in the ranking), SLC25A26
is essential for PEMT, i.e. the lack of SLC25A26 inhibits
PEMT since the latter cannot perform in sustained steady-
state without the former. From a different perspective, note
that the inhibition of SLC25A26 may lead to the accumula-
tion of SAH in mitochondria since, to our knowledge, this
enzyme is the only one consuming SAH in such compart-
ment. Following the hypothesis presented in Selley [51], this
would inhibit PEMT as mentioned in the previous dis-
cussion. In summary, from two different perspectives,
one theoretical and another experimental, we highlight
the importance of SLC25A26 to guarantee the activity
of PEMT, which is closely related with an accumulation
of HCys and AD [51].
Next enzyme appearing in Table 2 is Phosphatidylserine
decarboxylase (PISD), with ΔLj= 0.767. This mitochondrial
enzyme decarboxylases Phosphatidylserine (Pser) produ-
cing a molecule of PE and CO2. A direct effect when the
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has been indicated as a molecular signature of AD pa-
tients [52]. In addition to this, Salvador et al. [53], provides
insights of the decreased activity of PISD during aging,
which is known to increase the risk of suffering AD.
The last enzyme appearing in Table 2 is phospha-
tidylserine flippase (PSFLIP), also with ΔLj= 0.767.
PSFLIP is an ATP-consuming transporter of Pser from
the cytosol to the mitochondria. This enzyme helps to
maintain the membrane lipid bilayer asymmetry. When
asymmetric collapse occurs, a signaling mechanism of
synaptosomal apoptosis is triggered [54], as it occurs in
AD [55]. In Castegna et al. [54] it is proposed that the
oxidative environment characteristic in AD might contain
compounds that interfere with the activity of PSFLIP and
this may produce the unwanted asymmetric collapse.
Similar conclusions were presented by [56].
In conclusion, based on the literature, we found that the
deficit of PEMT seems to have a direct connection with
HCys accumulation in AD. Instead, the role of SLC25A26,
PISD and PSFLIP is hypothetical. As SLC25A26 is essen-
tial for the activity of PEMT, its implication in HCys accu-
mulation seems plausible, though additional experimental
evidence is required. With respect to PISD and PSFLIP,
we found an indirect association with HCys concentration
through shared AD diagnosis. As AD is a complex disease,
this link is not particularly compelling. Therefore, experi-
mental work is required to validate the role of PISD and
PSFLIP in HCys accumulation.
Conclusions
In this work, we present a novel network-based frame-
work to find candidate enzymes whose malfunction is
responsible for the accumulation of a given metabolite.
Our approach was applied to investigate the accumula-
tion of L-Cystine (LCystin) and Homocysteine (HCys) in
mental disorders. Results were then discussed based on
literature and found a good agreement with previously
reported mechanisms. In addition, we hypothesize a novel
role of several enzymes for the accumulation of these me-
tabolites, which opens new strategies to understand the
metabolic processes underlying these diseases. This is il-
lustrated, for example, with S-Adenosyl-L-methionine re-
versible transport (SLC25A26), whose relevance for the
accumulation of HCys, to our knowledge, has not been
previously reported.
Our in-silico framework is mainly founded on the
study of Connectivity Curves (CCs) of the metabolite
under study in different scenarios. In particular, CCs
summarize the pathway structure from an identified me-
tabolite and their underlying distances, which are used
as a clue for their fluxes. For the metabolite under study,
we evaluate changes in CCs when an enzyme j is removed
via ΔLj, namely based on the logic that an increase ofdistances in its degradation (biosynthesis) pathways poten-
tially explains its accumulation (depletion). The central
hypothesis here is that shorter pathways carry higher flux
than longer pathways. This assumption is supported by
several theoretical works and it seems plausible, particu-
larly according to the results obtained. However, the
integration of “omics” data into our approach, especially
proteomics and gene expression data, constitutes a future
research direction with the aim of providing a more realis-
tic pathway activity.
In order to complement the ranking arising from CCs,
we introduced a p-value for each enzyme, which is a
quantitative parameter indicating the specificity of a par-
ticular enzyme knockout/malfunction to explain the me-
tabolite alteration under consideration. For the sake of
simplicity, we preferably focused on enzymes with higher
specificity for the accumulation/depletion of the metab-
olite under study. However, a high p-value might not be
undesired for other biological questions, since complex
diseases may potentially present alterations in the con-
centration of more than one metabolite. This possibility
will be explored in the future.
In addition, in our approach we did not consider en-
zyme knockouts disrupting key cellular metabolic func-
tions. Despite the fact that metabolism is typically altered
in a disease scenario, we assume that essential functions
can be still accomplished in the absence of an enzyme. In
other words, we are not seeking lethal knockouts but pos-
sible malfunctions explaining the observed accumulations/
depletions. For this purpose, we only analyzed knockouts
not producing disconnections between medium metabo-
lites (substrates) and cellular excreted metabolites. Clearly,
this criterion can be revisited and modified according to
the biological scenario under study, e.g. forcing the pro-
duction of a particular set of metabolites required for
cellular growth.
In summary, our approach involves three main ingre-
dients: CCs and their parameters, p-value and filtering
criterion. These ingredients share the use of Carbon Flux
Paths (CFPs) for their determination. This pathway con-
cept was recently introduced and goes beyond path
finding techniques by accounting for additional bio-
physical constraints. In order to apply the CFP to the
human genome-scale metabolic network presented in
Duarte et al. [33], we manually built a database indicat-
ing input and output metabolites that exchange carbon
atoms in each of its reactions. This is now available for
further research.
The effect of CFPs is particularly observed when our
approach predicted the association of LCystin with the
enzyme Sulfite Oxidase (SULFOX). By definition, CFPs
involve carbon exchange in their intermediate reaction
steps. However, there is no carbon flux from LCystin to
any metabolite taking part in SULFOX, since they are
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reaction is important to mass balance the obtained paths
from LCystin to the rest of metabolites. This case also il-
lustrates the idea that enzymes at considerable distance
from the metabolite under consideration may regulate
its concentration.
Given the relevance of CFPs in the performance of our
approach, improving their accuracy is certainly relevant.
As noted in Pey et al. [26], CFPs must still face different
issues. In particular, guaranteeing carbon exchange be-
tween the source and target metabolites is essential and
this is not fully satisfied in their current format. We en-
sure carbon exchange in each of its intermediate steps,
but not between the source and target. In this direction,
the release of databases incorporating atomic mapping
of metabolites at large scale is promising [57].
In addition, our approach sacrificed some accuracy by
neglecting classical regulatory mechanisms with the aim to
extend our analysis to genome-scale metabolic networks.
Regulatory information is certainly relevant for explaining
changes in metabolite levels; however, it is scarce for
genome-scale networks. The issue will require further con-
sideration when such data becomes widely available.
Finally, we believe our approach will be a practical tool
to study poorly understood disease phenotypes. Extending
its application to other diseases (obesity, cancer, dia-
betes…) will be a major activity in the future, precisely
with the emergence of metabolomics studies. This work
contributes to the development of Systems Medicine, an
emerging field aiming to provide answers to clinical ques-
tions based on theoretical methods and high-throughput
“omics” data.Methods
Carbon Flux Paths (CFPs)
In Pey et al. [26], we presented details as to the mathemat-
ical formulation of the CFP approach. Similarly to other
graph-based methods for the analysis of metabolic net-
works, CFPs search for simple paths that link a pair of me-
tabolites. However, CFPs satisfy two additional properties:
i) ability to work in sustained steady-state; and ii) carbon
exchange in each of its intermediate steps. The CFP ap-
proach is an integer linear program. We summarize below
their main features.
min
XC
i¼1
XC
j¼1;j≠i
uij
subject to:
XC
j¼1
uαj ¼
XC
i¼1
uiβ ¼ 1 ð1ÞXC
i¼1
ujα ¼
XC
j¼1
uβj ¼ 0 ð2Þ
XC
i¼1
uik ¼
XC
j¼1
ukj k ¼ 1; :::;C; k≠α; β ð3Þ
XC
i¼1
uik≤1 k ¼ 1; :::;C ð4Þ
XR
r¼1
Scrvr ¼ 0 c ¼ 1; :::;C ð5Þ
zr≤vr≤Mzr r ¼ 1; :::;R ð6Þ
zλ þ zμ≤1 ∀ λ; μð Þ∈B ð7Þ
XR
r¼1;dijr¼1
zr≥uij i ¼ 1; :::;C; j ¼ 1; :::;C; i≠j ð8Þ
vr≥0 r ¼ 1; :::;R
zr∈ 0; 1f g r ¼ 1; :::;R
uij∈ 0; 1f g i ¼ 1; :::;C; j ¼ 1; :::;C; i≠j
A CFP constitutes a steady-state (balanced) flux distri-
bution that involves a directed path (in the graph theor-
etical sense) between a given source (α) and target (β)
metabolites. We first consider variables and constraints
to obtain a directed path between α and β. We then il-
lustrate constraints for steady-state flux distributions. Fi-
nally, both sets of constraints are linked.
Assume we have a metabolic network that comprises
R reactions and C metabolites. Let Scr be the stoichio-
metric coefficient associated with metabolite c in reac-
tion r. We used a (directed) graph representation of the
network where nodes are metabolites and arcs represent
carbon exchange between substrates and products of
reactions.
Binary variables uij stand for active arcs involved in
the directed path between α and β, namely uij = 1 when
an arc between metabolites i and j is active, uij = 0 other-
wise. By means of Equations (1) and (2) we ensure that
one arc leaves the source and one enters the target
metabolite; and that no arc enters the source nor leaves
the target. For intermediate metabolites in the path, the
number of arcs entering them must be equal to the
number of arcs leaving them, as imposed by Equation
(3). Equation (4) ensures that a metabolite cannot be
revisited in the path.
A steady-state flux distribution satisfies Equation (5).
Note that the continuous variable vr represents the flux
through reaction r (r=1,…,R), which by definition is non-
negative. We also define a set of binary variables zr
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and zr = 0 if vr = 0. We need Equation (6) to link vr and
zr variables. M is a big scalar constant that sets an upper
bound for reaction fluxes. Note that we split reversible
reactions into two single irreversible steps. Therefore,
we need to prevent a reaction and its reverse from
appearing together in any steady-state flux distribution.
This is modeled in Equation (7), where the set B={(λ,μ)|
reaction λ and reaction μ are the reverse of each other}.
Equation (8) is introduced to link path constraints,
Equations (1)-(4), and flux balancing constraints,
Equations (5)-(7), which guarantees that if an arc is se-
lected, at least one of the reactions r with an existing arc
(carbon exchange) between metabolites i and j (dijr = 1)
must carry flux. This last constraint ensures that the di-
rected path found can perform in sustained steady-state,
as claimed in Pey et al. [26].
Finally, we use an objective function that minimizes
the number of arcs in the directed path, i.e. the shortest
path between α and β. Further details can be found in
Pey et al. [26].
Average length increasing parameter (ΔLj)
The average length increasing parameter (ΔLj) provides
the difference in the average number of steps of metabo-
lites connected to the metabolite under study between a
knockout (K) scenario of enzyme j (LKj ) and the wild-
type (W) scenario (LWj ), as observed in Equation (9). We
detail below how to calculate this parameter.
ΔLj ¼ LKj −LWj ð9Þ
Dmax;Kj ¼ argminx CK ;jx
  ¼ CK ;j∞   ð10Þ
Dmax;W ¼ argminx CWx
  ¼ CW∞   ð11Þ
LKj ¼
XDmax;Kj
i¼1 C
K ;j
i
 − CK ;ji−1
  ⋅i
CK ;j∞
  ð12Þ
LWj ¼
XDmax;W
i¼1 C
W
i ∩C
K ;j
∞
 − CWi−1∩CK ;j∞  ⋅i
CK ;j∞
  ð13Þ
CK ;ji is the set of metabolites connected to the source
metabolite in at most i steps when enzyme j is knocked
out, while CWi is the same value in the wild-type scenario;
CK ;ji
  and CWi  are the cardinality of sets CK ;ji and CWi ,
respectively. CK ;j∞ is the set of metabolites connected to
the source metabolite after moving ∞ steps away. In other
words, CK ;j∞ represents the full set of metabolites
connected to the source metabolite when enzyme j is
knocked out, being CK ;j∞
  its cardinality. CW∞ and CW∞ 
represent the same in the wild-type scenario.As observed in Equation (10), Dmax;Kj is the minimum
distance required to reach the full set of metabolites
connected the metabolite under study when enzyme j is
knocked out (CK ;j∞ ); D
max,W represents the same value in
the wild-type scenario (see Equation (11)).
LKj and L
W
j average distances among metabolites
connected to the source metabolite in the knockout and
wild-type scenarios, respectively. See Equations (12)-
(13). Note here that, in order to compare both scenarios,
we only considered those metabolites that remain con-
nected when enzyme j is knocked out. For this reason, we
used the intersection expression in Equation (13).
Enzyme p-value calculation
The p-value defines the probability of obtaining an at
least as extreme outcome according to a predefined Null
Hypothesis (H0). Therefore, an adequate H0 must be de-
fined in the first place. In our particular statistical test,
H0 represents that the ranking of an enzyme is not de-
termined by the accumulated metabolite under study. In
other words, the resulting positions of the enzymes in
the ranking derived from our approach are not specific
of the metabolite under study.
Based on this H0 definition, an appropriate distribu-
tion function should be introduced. We define a set of
positions Xi for a particular enzyme j regarding the accu-
mulation of N different metabolites (X1, X2 … XN). We
assume that all the variables Xi come from the same the-
oretical distribution F. In addition, we introduce F*N as
the cumulative sampling distribution associated with the
random sample set (X1, X2 … XN). In essence, F*N as-
cribes a probability equal to 1/N to each of the sample
observations. The formal representation of F*N is presented
in Equation (14). Note here that x represents a given pos-
ition in the ranking of enzyme j.
FN xð Þ ¼
1
N
XN
i¼1
I −∞;xð  Xið Þ ∀x∈R ð14Þ
Note that IA(y) is the indicator function corresponding
to the set A:
IA yð Þ ¼ 1 if y∈A0 if y∉A

ð15Þ
Once F*N is correctly defined, the calculation of the
p-values corresponding to a determined ranking is
straightforward. Assuming that enzyme j appears in the
k-th position in a particular ranking, the corresponding
p-value is calculated as follows:
pvalue kð Þ ¼ FN kð Þ ð16Þ
In the case study Results section, we selected 1000
random metabolites and ranked enzymes based on the
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for each enzyme in the different scenarios (1000 random
metabolite accumulation) is used to build its empirical
distribution (F*N). This is then used to determine the p-
value associated with the enzymes top-ranked in the me-
tabolites under study.
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